Contents

Current Cancer Drug Targets, Volume 10 - Number 4

Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics

, 10(4): 354 - 367

M.R. Pitman and S.M. Pitson


DOI: 10.2174/156800910791208599




Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent

, 10(4): 368 - 383

L. Tentori, A. Muzi, A.S. Dorio, M. Scarsella, C. Leonetti, G.M. Shah, W. Xu, E. Camaioni, B. Gold, R. Pellicciari, F. Dantzer, J. Zhang and G. Graziani


DOI: 10.2174/156800910791208571




Targeting CREB for Cancer Therapy: Friend or Foe

, 10(4): 384 - 391

X. Xiao, B.X. Li, B. Mitton, A. Ikeda and K.M. Sakamoto


DOI: 10.2174/156800910791208535




Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer

, 10(4): 392 - 401

B. Wegiel, S. Evans, R. Hellsten, L.E. Otterbein, A. Bjartell and J.L. Persson


DOI: 10.2174/156800910791208562




Recent Advances in Understanding Hormonal Therapy Resistant Prostate Cancer

, 10(4): 402 - 410

K.V. Donkena, H. Yuan and C.Y. Young


DOI: 10.2174/156800910791208544




Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy

, 10(4): 411 - 421

S. Cruet-Hennequart, A.M. Prendergast, F.P. Barry and M.P. Carty


DOI: 10.2174/156800910791208553




Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells

, 10(4): 422 - 431

S. Carloni, F. Fabbri, G. Brigliadori, P. Ulivi, R. Silvestrini, D. Amadori and W. Zoli


DOI: 10.2174/156800910791208580




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science